Supernus Pharmaceuticals, Inc. (SUPN)

NGM – Real Time Price. Currency in USD

46.82

-0.06 (-0.13%)

Market open: Aug 12, 2026, 2:42 PM EDT

46.88

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

719M

662M

608M

667M

Cost of goods sold

-166M

-158M

-169M

-173M

Gross Profit

553M

503M

439M

494M

Operating expenses (excl. COGS)

-590M

-442M

-425M

-449M

Operating Income

-37M

61M

13M

46M

Non-operating income, total

-12M

37M

-11M

15M

Pretax income

-49M

98M

61M

Equity in earnings

Taxes

10M

-24M

-1M

-32K

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

-39M

74M

61M

Discontinued operations

Net income

-39M

74M

61M

Dilution adjustment

Preferred dividends

Supernus Pharmaceuticals, Inc. (SUPN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Supernus Pharmaceuticals, Inc. (SUPN)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Supernus Pharmaceuticals, Inc. (SUPN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Supernus Pharmaceuticals, Inc. (SUPN)

Income Statement (Annual)

Income Statement (Annual)